Skip to Content

Morphine Injection

Last Updated: April 20, 2018
Status: Current

Morphine Injection

Products Affected - Description
    • Duramorph (preservative-free) injection, West-Ward, 0.5 mg/mL, 10 mL ampule, 10 count, NDC 00641-6020-10
    • Duramorph (preservative-free) injection, West-Ward, 1 mg/mL, 10 mL ampule, 10 count, NDC 00641-6019-10
    • Infumorph (preservative-free) injection, West-Ward, 10 mg/mL, 20 mL ampule, 1 count, NDC 00641-6039-01
    • Infumorph (preservative-free) injection, West-Ward, 25 mg/mL, 20 mL ampule, 1 count, NDC 00641-6040-01
    • Morphine injection, Fresenius Kabi, 10 mg/mL, 1 mL preservative-free prefilled syringe, 24 count, NDC 76045-0008-10
    • Morphine injection, Fresenius Kabi, 2 mg/mL, 1 mL preservative-free prefilled syringe, 24 count, NDC 76045-0004-10
    • Morphine injection, Fresenius Kabi, 4 mg/mL, 1 mL preservative-free prefilled syringe, 24 count, NDC 76045-0005-10
    • Morphine injection, Fresenius Kabi, 5 mg/mL, 1 mL preservative-free prefilled syringe, 24 count, NDC 76045-0006-10
    • Morphine injection, Fresenius Kabi, 8 mg/mL, 1 mL preservative-free prefilled syringe, 24 count, NDC 76045-0007-10
    • Morphine injection, Pfizer, 0.5 mg/mL, 10 mL preservative-free vial, 25 count, NDC 00409-3814-12
    • Morphine injection, Pfizer, 1 mg/mL, 10 mL preservative-free vial, 25 count, NDC 00409-3815-12
    • Morphine injection, Pfizer, 10 mg/mL, 1 mL preservative-free Carpuject syringe, 10 count, NDC 00409-1893-01
    • Morphine injection, Pfizer, 10 mg/mL, 1 mL preservative-free iSecure syringe, 10 count, NDC 00409-1893-11
    • Morphine injection, Pfizer, 2 mg/mL, 1 mL preservative-free Carpuject syringe, 10 count, NDC 00409-1890-01
    • Morphine injection, Pfizer, 2 mg/mL, 1 mL preservative-free iSecure syringe, 10 count, NDC 00409-1890-11
    • Morphine injection, Pfizer, 25 mg/mL, 1 mL preservative-free vial, 50 count, NDC 00409-1135-02
    • Morphine injection, Pfizer, 4 mg/mL, 1 mL preservative-free Carpuject syringe, 10 count, NDC 00409-1891-01
    • Morphine injection, Pfizer, 4 mg/mL, 1 mL preservative-free iSecure syringe, 10 count, NDC 00409-1891-11
    • Morphine injection, Pfizer, 50 mg/mL, 20 mL vial, 50 count, NDC 00409-1134-03
    • Morphine injection, Pfizer, 50 mg/mL, 50 mL vial, 50 count, NDC 00409-1134-05
    • Morphine injection, Pfizer, 8 mg/mL, 1 mL preservative-free Carpuject syringe, 10 count, NDC 00409-1892-01
    • Morphine injection, Pfizer, 8 mg/mL, 1 mL preservative-free iSecure syringe, 10 count, NDC 00409-1892-11
    • Morphine injection, West-Ward, 10 mg/mL, 1 mL vial, 25 count, NDC 00641-6127-25
    • Morphine injection, West-Ward, 4 mg/mL, 1 mL vial, 25 count, NDC 00641-6125-25
    • Morphine injection, West-Ward, 8 mg/mL, 1 mL vial, 25 count, NDC 00641-6126-25
Reason for the Shortage
    • Fresenius Kabi procured morphine syringes from BD in 2016. They discontinued the 8 mg/mL and 10 mg/mL 1 mL syringes in early-2018.[1-2]
    • Astramorph injection has been unavailable since 2012. Fresenius Kabi changed manufacturing sites and cannot estimate if Astramorph will return.[2]
    • Pfizer states the shortage is due to manufacturing delays. Pfizer discontinued morphine ADD-Vantage vials in January 2017.[3]
    • Pfizer anticipates a shortage of several prefilled syringe products, including morphine, starting in late-July 2017 due to issues at a manufacturing facility. To minimize the impact of the shortage, Pfizer is prioritizing production of certain morphine Carpuject syringes. Pfizer expects the shortage of prefilled syringe products to recover by late-first quarter 2018.[3]
    • West-Ward did not provide a reason for the shortage. West-Ward is not actively marketing the 15 mg/mL 1 mL vials or the 8 mg/mL 1 mL vials (NDC 00641-6075-25). They are still marketing the 8 mg/mL 1 mL vials with NDC 00641-6126-25.[4]

Estimated Resupply Dates

    • Fresenius Kabi has morphine 2 mg/mL 1 mL syringes on back order and the company estimates a release date of early-May 2018. The morphine 4 mg/mL 1 mL and 5 mg/mL 1 mL syringes are on back order and the company cannot estimate a release date. Check wholesalers for inventory.[2]
    • Pfizer has morphine 2 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of July 2018. The 4 mg/mL 1 mL Carpuject syringes are on back order and the company cannot estimate a release date. The 0.5 mg/mL and 1 mg/mL 10 mL preservative-free vials are on back order and the company estimates a release date of May 2018. The 8 mg/mL 1 mL iSecure syringes are on back order and the company estimates a release date of March 2019. The 2 mg/mL 1 mL iSecure syringes, 4 mg/mL 1 mL iSecure syringes, 8 mg/mL 1 mL Carpuject syringes, 10 mg/mL 1 mL iSecure syringes, and 10 mg/mL 1 mL Carpuject syringes are on back order and the company estimates a release date of June 2019. The 25 mg/mL 1 mL preservative-free vials are on back order and the company estimates a release date of late-May 2018. The 50 mg/mL 20 mL and 50 mL vials are on back order and the company estimates a release date of June 2018 for the 20 mL vials and May 2018 for the 50 mL vials.[3]
    • West-Ward has morphine 4 mg/mL 1 mL vials, 8 mg/mL 1 mL vials, and 10 mg/mL 1 mL vials on allocation. Infumorph 10 mg/mL 20 mL ampules and 25 mg/mL 20 mL ampules are on back order and the company cannot estimate a release date. Duramorph 1 mg/mL 10 mL ampules are on back order and the company cannot estimate a release date. Duramorph 0.5 mg/mL 10 mL ampules are on alloction.[4]

Implications for Patient Care

    • ASHP has an FAQ on the injectable opioid shortage at https://www.ashp.org/Drug-Shortages/Shortage-Resources/Injectable-Opioid-Shortages-FAQ. This discusses multiple issues including inventory and pharmacy operational strategies.

Safety

    • Exercise extreme caution when switching morphine concentrations or interchanging to other injectable opioid products (eg, hydromorphone). Equianalgesic dosing conversions are based on limited data and do not account for patient specific factors (eg, end organ function, pharmacogenomics) or incomplete cross-tolerance between opioids. No equianalgesic dosing conversion factors are universally accepted.[5-6]

Alternative Agents & Management

    • Use oral opioid dosage forms if the enteral route is available.[7]
    • Use patient controlled analgesia (PCA) presentations or prepare PCAs from multidose vials to conserve unit dose presentations. Patient controlled analgesia is the preferred method of parenteral opioid administration in postoperative patients.[7]
    • Work with prescribers to convert to an appropriate dose of another parenteral opioid if needed and available.

References

    1. BD (personal communications). October 2, 2015.
    2. Fresenius Kabi (personal communication). May 6 and 23, June 8, August 1 and 18, September 21, October 6, November 7, December 19, 2016; January 24, April 24, June 2, July 6 and 19, August 10, September 7, 21, and 28, October 27, November 10, 17, and 30, December 10, 15, and 17, 2017; January 12, February 5 and 15, March 2, 16, and 23, and April 6 and 13, 2018.
    3. Pfizer (personal communication and website). September 4 and 18, October 2 and 19, November 17 and 30, December 17 and 23, 2015; January 14, February 22, April 11, May 4, 10, 18, and 25, June 2, 17, and 23, August 1 and 25, September 6, October 8, November 10, December 19, 2016; January 24, February 22 and 24, May 4, June 2, 9, and 21, July 7, 25, and 31, August 11, September 6, 11, and 25, October 4, November 2, 15, and 28, December 5, 11, and 29, 2017; January 5 and 18, February 2 and 16, March 5, 16, and 23, and April 9 and 20, 2018.
    4. West-Ward (personal communication). August 12 and 26, September 15 and 30, October 1 and 15, November 30, December 14, 2015; January 6 and 28, February 18 and 28, March 29, April 11, May 3, 13, and 24, June 17, August 1 and 10, September 29, November 2, December 19, 2016; January 25, February 24, May 3, June 7, July 5 and 19, August 10, September 6, 22, and 29, October 27, November 9, 22, and 30, December 7, 14, and 20, 2017; January 5 and 18, February 1, 14, and 28, March 21, and April 4 and 18, 2018.
    5. Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonica's Management of Pain. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2010.
    6. McPherson ML, ed. Demystifying Opioid Conversion Calculations. Bethesda, MD: American Society of Health-System Pharmacists; 2010.
    7. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131-157.

Updated

Updated April 20, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 16, 2009 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide